LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Aalto Bio Launches Lysis Buffer Reagent for COVID-19 Testing

By LabMedica International staff writers
Posted on 02 May 2020
Illustration
Illustration
Aalto Bio Reagents Ltd. (Dublin, Ireland), a supplier of critical raw materials and reagents for diagnostic tests, has launched its first RNA lysis buffer reagent for the pre-treatment of COVID 19 samples prior to testing.

This essential RNA Lysis buffer was produced by Aalto Bio due to the unavailability of similar reagents from other manufacturers in Europe. The volume of PCR tests being carried out for COVID-19 in Ireland as well as across the world is such that manufacturers simply cannot produce the volume of reagents required. In March 2020, Aalto Bio was contacted by Ireland's Health Service Executive (HSE) to see if the company could refocus its manufacturing and development capabilities to provide a RNA lysis buffer which would be used by hospitals and laboratories for COVID-19 testing. Within four weeks of being contacted, the first bulk order was shipped to the National Virus Reference Laboratory in UCD where most of Ireland's testing is being carried out.

“At Aalto Bio, we were happy to assist the HSE by producing this critical reagent to help alleviate some of the pressure that has been brought on the system by COVID-19. As the HSE continues to expand on its testing capabilities we expect the demand for critical raw material such as ours to grow, and we are prepared to offer our services when needed. As a wholly-owned Irish diagnostics company we are proud to be able to contribute towards the testing regime of COVID-19,” said Philip Noone, CEO, Aalto Bio Reagents.

Related Links:
Aalto Bio Reagents Ltd.

Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Ketosis and DKA Test
D-3-Hydroxybutyrate (Ranbut) Assay
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080

Channels

Hematology

view channel
Image: Research has linked platelet aggregation in midlife blood samples to early brain markers of Alzheimer’s (Photo courtesy of Shutterstock)

Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk

Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
GLOBE SCIENTIFIC, LLC